The combination of carboplatin and karelizumab is able to treat advanced squamous lung cancer. Karelizumab combined with carboplatin + pemetrexed is the first-line treatment for non-small cell lung cancer, so it can treat squamous lung cancer. Karelizumab belongs to the immunotherapy, and some evaluation should be done before carrying out the treatment, and there is a very common side effect of karelizumab, which is hemangioma and hypothyroidism. Therefore, after applying Karelizumab, it is necessary to observe whether some hemangiomas have arisen on the body, and it is also necessary to regularly review the thyroid function to see whether hypothyroidism occurs, and carboplatin has a relatively large impact on blood, so it is necessary to regularly review the blood routine. When treating squamous lung cancer, you need to go to regular hospitals to combine your own situation to make chemotherapy program, do not use drugs on your own.